JP2016519051A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519051A5
JP2016519051A5 JP2015562159A JP2015562159A JP2016519051A5 JP 2016519051 A5 JP2016519051 A5 JP 2016519051A5 JP 2015562159 A JP2015562159 A JP 2015562159A JP 2015562159 A JP2015562159 A JP 2015562159A JP 2016519051 A5 JP2016519051 A5 JP 2016519051A5
Authority
JP
Japan
Prior art keywords
amino acid
pcsk9
mutein
tear lipocalin
human tear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519051A (ja
JP6619650B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055013 external-priority patent/WO2014140210A1/en
Publication of JP2016519051A publication Critical patent/JP2016519051A/ja
Publication of JP2016519051A5 publication Critical patent/JP2016519051A5/ja
Application granted granted Critical
Publication of JP6619650B2 publication Critical patent/JP6619650B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562159A 2013-03-14 2014-03-13 新規のpcsk9結合タンパク質 Expired - Fee Related JP6619650B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781511P 2013-03-14 2013-03-14
US61/781,511 2013-03-14
EP13175023.4 2013-07-04
EP13175023 2013-07-04
PCT/EP2014/055013 WO2014140210A1 (en) 2013-03-14 2014-03-13 Novel binding proteins for pcsk9

Publications (3)

Publication Number Publication Date
JP2016519051A JP2016519051A (ja) 2016-06-30
JP2016519051A5 true JP2016519051A5 (enExample) 2017-04-13
JP6619650B2 JP6619650B2 (ja) 2019-12-11

Family

ID=48703321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562159A Expired - Fee Related JP6619650B2 (ja) 2013-03-14 2014-03-13 新規のpcsk9結合タンパク質

Country Status (15)

Country Link
US (3) US9150629B2 (enExample)
EP (1) EP2968490A1 (enExample)
JP (1) JP6619650B2 (enExample)
KR (1) KR20150131151A (enExample)
CN (1) CN105246503A (enExample)
AU (1) AU2014230460B2 (enExample)
BR (1) BR112015021681A2 (enExample)
CA (1) CA2905186A1 (enExample)
HK (1) HK1213194A1 (enExample)
IL (1) IL241329A0 (enExample)
MX (1) MX2015012420A (enExample)
PH (1) PH12015501687A1 (enExample)
RU (1) RU2015142437A (enExample)
SG (1) SG11201505856TA (enExample)
WO (1) WO2014140210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
CA2905186A1 (en) 2013-03-14 2014-09-18 Daiichi Sankyo Co., Ltd Novel binding proteins for pcsk9
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
US9398085B2 (en) 2014-11-07 2016-07-19 Ringcentral, Inc. Systems and methods for initiating a peer-to-peer communication session
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CA3115341A1 (en) 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US11814445B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
WO2022021000A1 (zh) * 2020-07-27 2022-02-03 深圳华大生命科学研究院 一种抗体结合的特征性表位及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
AT411852B (de) 2002-02-12 2004-06-25 Didosyan Yuri S Dr Verfahren und vorrichtung zur änderung des polarisationszustandes von licht mit einem magnetisch einachsigen kristall
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
JP5588175B2 (ja) * 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Pcsk9のアンタゴニスト
CA2668131A1 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
TW200906439A (en) * 2007-04-13 2009-02-16 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
SMT201900297T1 (it) * 2010-06-08 2019-07-11 Astrazeneca Ab Muteine di lipocalina lacrimale che si legano a il-4 r alfa
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
EP2802341B1 (en) * 2012-01-09 2019-03-06 Pieris Pharmaceuticals GmbH Methods for preventing, treating or diagnosing disorders
CA2905186A1 (en) 2013-03-14 2014-09-18 Daiichi Sankyo Co., Ltd Novel binding proteins for pcsk9

Similar Documents

Publication Publication Date Title
JP2016519051A5 (enExample)
RU2015142437A (ru) Новые связывающие белки для pcsk9
EP3015477B1 (en) High-stability t-cell receptor and preparation method and application thereof
JP2018532372A5 (enExample)
Iyengar et al. The complete amino‐acid sequence of the sweet protein thaumatin I
JP2018526989A5 (enExample)
JP2013537400A5 (enExample)
RU2012150766A (ru) Мутеины липокалина слезы, связывающие альфа il-4 r
JP2018519803A5 (enExample)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2018515085A5 (enExample)
JP2018515084A5 (enExample)
RU2015137158A (ru) МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
JP2012531212A5 (enExample)
JP2016505826A5 (enExample)
JPH06508742A (ja) 組換えトロンビンレセプターおよびそれに関連した薬剤
JP2014500724A5 (enExample)
ATE517118T1 (de) Bis-met-histone
JP2019506140A5 (enExample)
RU2017135605A (ru) Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)
AU2020200990A1 (en) Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
CN108025059B (zh) 抗猫过敏的组合物
EP3299389A1 (en) Soluble and stable heterodimeric tcr
JP2017502003A (ja) プロテアーゼ耐性ペプチド
CA3195315A1 (en) Compositions and methods for selective depletion of target molecules